Physician profile
Daniel Lew
NPI 1669859666
$3,347.98
in general payments reported to CMS, 2019-2025
10 companies · $781 in 2025
The $781 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $125 · 2020: $31.58 · 2021: $1,046 · 2022: $116 · 2023: $25.75 · 2024: $1,224 · 2025: $781.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,227 · Food and Beverage: $803.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,227.00 |
| Food and Beverage | $803.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $2,863.70 | 2021-2025 | Axios, Orise, Overstitch Nxt Endoscopic Suturing System |
| Micro-Tech Endoscopy USA, INC. | $140.03 | 2024 | |
| Galderma Laboratories, L.P. | $124.52 | 2019 | |
| Inspire Medical Systems, INC. | $85.76 | 2024 | Inspire |
| Gilead Sciences, INC. | $31.58 | 2020 | |
| Seqirus USA INC | $27.07 | 2025 | Fluad, Flucelvax |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $21.78 | 2025 | Caplyta |
| Vertex Pharmaceuticals Incorporated | $19.05 | 2025 | |
| Insulet Corporation | $18.74 | 2025 | Omnipod |
| Glaxosmithkline, LLC. | $15.75 | 2025 | Shingrix, Arexvy, Bexsero |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Lew listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.